SLC30A8 and type 2 diabetes mellitus: ZnT8 is a novel islet autoantigen for T1DM, and it has been shown that ZnT8 was targeted by autoantibodies in 60–80% of new-onset T1DM patients, which occurred in only 2% of controls, 3% of T2DM patients, and 30% of patients with other autoimmune diseases associated with T1DM [108, 110].